Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01441921
Other study ID # PV11059S
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2011
Est. completion date September 2017

Study information

Verified date February 2019
Source Institut Investigacio Sanitaria Pere Virgili
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hypothesis: Chronic intake of pistachios improves glucose metabolism and insulin resistance status thus contributing to decrease the risk of type 2 diabetes mellitus and its associated abnormalities.


Description:

In free-living overweight or obese adult with impaired fasting glucose or impaired glucose tolerance we will compare the effects of a pistachio-rich diet or a Mediterranean Diet on:

- Fasting glucose levels, hemoglobin A1c, insulin, C peptide, HOMA IR, advanced glycation end products and soluble receptor of advanced glycation-end products.

- Peripheral haemostatic parameters.

- Plasma inflammatory markers.

- Lymphocyte expression of toll-like receptors, C peptide, resistin and interleukin-6 in peripheral leukocytes.

- Lymphocyte glucose transport and expression of glucose transporter 4 in peripheral blood leukocytes.

- Platelet function including platelet number, mean platelet volume, platelet factor 4 levels and urinary 11-dehydro-thromboxane B2.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date September 2017
Est. primary completion date September 2016
Accepts healthy volunteers No
Gender All
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria:

- BMI less than 35 kg/m2.

- Fasting plasma glucose levels between 100 and 125 mg/dl or

- Oral glucose tolerance test of 140 to 199 mg/dl.

Exclusion Criteria:

- Diabetes mellitus.

- Alcohol, tobacco, or drug abuse.

- Significant liver, kidney, thyroid, or other endocrine diseases.

- Frequent consumption of nuts or known history of allergy to them.

- Use of plant sterol, oral antidiabetic drugs, supplemental use of phyllium, fish oil supplements and multivitamins, vitamin E or other antioxidant supplements.

- Bad dentures, implying difficulty to chew pistachios.

- Being pregnant or wishing to become a pregnant 6 months before or during the study, lactating 6wk before or during the study.

- Following vegetarian or weight loss diets.

- Other medical or social conditions that difficult the compliance to the intervention.

Study Design


Intervention

Dietary Supplement:
Pistachios
Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period. Total duration of intervention and follow-up is nine months.
Other:
control diet
Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period. Total duration of intervention and follow-up is nine months.

Locations

Country Name City State
Spain Human Nutrition Unit, Faculty of Medicine, Rovira i Virgili University Reus Tarragona

Sponsors (2)

Lead Sponsor Collaborator
Institut Investigacio Sanitaria Pere Virgili Western Pistachio Association

Country where clinical trial is conducted

Spain, 

References & Publications (4)

Hernández-Alonso P, Cañueto D, Giardina S, Salas-Salvadó J, Cañellas N, Correig X, Bulló M. Effect of pistachio consumption on the modulation of urinary gut microbiota-related metabolites in prediabetic subjects. J Nutr Biochem. 2017 Jul;45:48-53. doi: 10 — View Citation

Hernández-Alonso P, Giardina S, Salas-Salvadó J, Arcelin P, Bulló M. Chronic pistachio intake modulates circulating microRNAs related to glucose metabolism and insulin resistance in prediabetic subjects. Eur J Nutr. 2017 Sep;56(6):2181-2191. doi: 10.1007/ — View Citation

Hernández-Alonso P, Salas-Salvadó J, Baldrich-Mora M, Juanola-Falgarona M, Bulló M. Beneficial effect of pistachio consumption on glucose metabolism, insulin resistance, inflammation, and related metabolic risk markers: a randomized clinical trial. Diabet — View Citation

Hernández-Alonso P, Salas-Salvadó J, Baldrich-Mora M, Mallol R, Correig X, Bulló M. Effect of pistachio consumption on plasma lipoprotein subclasses in pre-diabetic subjects. Nutr Metab Cardiovasc Dis. 2015 Apr;25(4):396-402. doi: 10.1016/j.numecd.2015.01.013. Epub 2015 Feb 7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Changes from baseline in circulating levels of glucose and insulin according to the intervention arm Measurement of circulating glucose and insulin levels and cellular glucose uptake Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm
Secondary Changes from baseline in inflammatory, oxidative and metabolic risk markers related to glucose/insulin metabolism according to the intervention arm Cpeptide, resistin, IL-6, IL-18, Ghrelin, leptin, adiponectin, GLP-1 and oxidized LDL will be measured. Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm
Secondary Changes from baseline in haemostatic parameters according to the intervention arm Tissue factor, fibrinogen, PAI-1, vWF will be measured. Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm
Secondary Changes from baseline in HL and LDL size according to the intervention arm Plasmi lipoprotein size will be measured by polycacrylamide gradient gel electrophoresis Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm
Secondary Changes in advanced glycation end products according to the intervention arm Advanced glycation end products and soluble receptor of advanced glycation-end produtcs will be measured Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm
Secondary Changes from baseline in gene expression in the peripheral cells according to the intervention arm RNA from peripheral leukocytes will be isolated for the subsequent measurements of changes in gene expression of toll-like receptors, GLUT-4, C-peptide, resistin adn IL-6, and genes involved in telomere maintenance and oxidation Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm
Secondary Changes from baseline in cellular glucose uptake according to the intervention arm Glucose uptake and GLUT4 protein levels will be assessed in peripheral leukocytes Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm
Secondary Changes from baseline in platelet function according to the intervention arm Platelet number, mean platelet volume and platelet factor 4 in blood, and urinary levels of 11-dehydro-thromboxane B2 will be assessed. Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm
Secondary Changes from baseline in telomeric length of leukocytes (LTL) Telomere lenght will be evaluated as a biomarker of biological age and general health status. Telomere attrition may play an important role in the pathogenesis and severity of type 2 diabetes (T2D) increasing the probability of beta-cell senescence, leading to reduced cell mass and decreased insulin secretion. Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first intervention arm. Measurements will be not analysed after the second period due to expected carry-over effect.
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02252224 - Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance

External Links